EU medical device regulation

Q&A: All you Need to Know About the New EU Medical Device Regulation (MDR)

Q&A: All you Need to Know About the New EU Medical Device Regulation (MDR)

EU medical device regulation

Until now, the rules for medical device manufacturers in Europe were laid out in the EU Medical Device Directive (93/42/EEC). In effect since 1993, this decades-old regulatory framework will be replaced by the EU’s Medical Device Regulation (MDR) (2017/745). The latter was published on May 2017 and will be coming into force on May 2020, after a transition period of 3 years. At the time of writing, this leaves manufacturers exactly a year to conform with the MDR.

Being a more inclusive yet more strict regulatory framework, the MDR can be considered a modern update of the existing medical device directive. This article is a brief summary in the form of a Q&A, about the key changes and most important points of the new EU medical device regulation.

Q&A: New EU Medical Device Regulation

What is MDR’s Scope Compared to the Previous Directive?

The MDR has an expanded scope to include devices that are not strictly intended for medical purposes. Such device examples are cosmetic implants and colored contact lenses.

What are the Major Quality Changes with MDR?

Firstly as is already the case with pharmaceuticals, the role of Qualified Person (QP) is introduced under the MDR. So a manufacturer defined Qualified Person will assume full responsibility for medical device compliance, under the MDR. Secondly, the MDR mandates the use of Unique Device Identification (UDI) mechanisms. These allow for fast tracking and tracing of every medical device anywhere in the supply chain, for both the authorities and manufacturers, ultimately aiding in more effective medical device products recalls. Lastly, the new EU medical device regulation will allow the Commission with the aid of expert panels, to define and publish Common Specifications. These will need to be taken into account by both Notified Bodies and medical device manufacturers.

What is the MDR’s Approach on Clinical Data?

One big change is that MDR requires more comprehensive clinical evidence for high risk medical devices, such as class III and implants. These need to cover any claims regarding both performance and safety of a medical device. Moreover, manufacturers will need to assess potential safety risks with clinical data acquired post market, after the medical devices have been marketed and are in widespread use.

Regarding classes IIa and IIb medical devices, clinical evaluation will need to be repeated according to the new EU medical device regulation. As a result, manufacturers may need to conduct a new clinical investigation, or take an equivalence approach and justify why their existing clinical investigation is adequate.

Will Existing Approved Medical Devices Be Affected?

Yes, as every currently approved medical device must be recertified, under the new MDR. Moreover, the MDR requires medical device manufacturers to harmonize their technical documentation according to the new regulation. Then by taking into account the application risk, invasiveness, and duration of contact, manufacturers are to assess whether it is necessary for them to reclassify their medical devices.

Read More

Medical device manufacturing

Common Mistakes when Transferring Medical Device Manufacturing to High Volume

In the following article we cover some of the common mistakes that are made when transferring medical device manufacturing to high volume. The ability to identify these areas at an early stage together with proper management, can be critical to a medical device’s lifecycle. These common pitfalls that result in costly corrective actions can be avoided altogether.

Read more...

Case Study: Plastic Molding DFM

Introduction It’s not uncommon for companies to seek a device manufacturer after having completed the prototype development phase. That’s because they mistakenly assume that the product development team has manufacturability in mind. On the contrary however, experience shows that during development, engineers will focus on design outputs to meet the design inputs. And not enough focus goes into product manufacturability as is necessary. It is absolutely critical to involve the device manufacturer from early on in the design phase. Otherwise, companies run the risk of developing products that will have issues with manufacturability that pose serious challenges in later stages. This study [...]

Read more...